Novocure’s experimental therapy using Tumor Treating Fields alongside chemotherapy showed positive results in extending the lives of patients with advanced pancreatic cancer in a late-stage trial. The therapy, which uses electric fields to target cancer cells while sparing healthy cells, helped patients live an average of 16.20 months compared to 14.16 months with chemotherapy alone. The treatment’s safety was consistent with prior studies and also improved survival rates over time. Novocure plans to seek regulatory approval in multiple markets. The therapy, already approved for other cancers, brought in significant revenue in 2023. Pancreatic cancer is a significant cause of cancer deaths in the U.S.
Source link
Novocure’s Pancreatic Cancer Treatment Meets Main Goal in Late-stage Study
